AuraVax Secures Gates Foundation Grant for NanoSTING-001 Influenza Challenge Study
核心洞察
AuraVax Therapeutics (搜索) has received funding from the Gates Foundation to evaluate NanoSTING-001 in swine influenza models at Kansas State University and The Pirbright Institute.
NanoSTING-001 is a broad-spectrum host-directed therapeutic that uses lipid nanoparticles to deliver STING (搜索) pathway activators for respiratory infection prevention and treatment.
Preclinical studies demonstrated the intranasal therapeutic prevents and treats influenza A and B, including Tamiflu-resistant strains and highly pathogenic avian influenza H5N1.
AuraVax Therapeutics (搜索) has secured funding from the Gates Foundation to advance its novel respiratory infection therapeutic through critical animal studies. The Houston-based biotechnology company will evaluate NanoSTING-001 in swine disease models at Kansas State University College of Veterinary Medicine and The Pirbright Institute in the United Kingdom.
Novel STING Pathway Approach
NanoSTING-001 represents a new class of host-directed therapeutics designed to activate the innate immune response within the respiratory tract. The treatment uses lipid nanoparticles to deliver a natural activator of the stimulator of interferon genes (STING (搜索)) pathway, providing loco-regional immune enhancement. This approach is intended for use both before and after pathogen exposure to prevent respiratory infections and reduce severe illness risk.
The therapeutic is being developed to provide broad-spectrum protection independent of the specific respiratory pathogen, offering potential advantages over pathogen-specific treatments. Host-directed therapies targeting the innate immune system achieve protection independent of vaccination and hold promise for prevention and treatment of illnesses from multiple respiratory threats.
Preclinical Efficacy Data
Preclinical testing has demonstrated encouraging results for NanoSTING-001's safety and efficacy profile. The candidate therapeutic appears well tolerated, rapidly activates innate immunity, and treats consequences of infection. Notably, intranasal NanoSTING-001 has shown effectiveness against influenza A and B, including strains resistant to Oseltamivir (Tamiflu) and highly pathogenic avian influenza H5N1.
The upcoming swine studies will assess NanoSTING-001's ability to protect pigs from influenza infection, providing crucial efficacy data to inform clinical trial design. These validated animal models represent an important step toward human testing of the therapeutic.
Addressing Respiratory Disease Burden
The development comes as respiratory pathogens continue to impose significant clinical and economic burdens. During the 2024-2025 season in the United States, the CDC estimates 47 to 82 million flu illnesses, 610,000 to 1.3 million influenza-related hospitalizations, and 27,000 to 130,000 influenza deaths.
"We are pleased to work with K-State and Pirbright to conduct studies in validated swine models of influenza infection," said Joseph Sullivan, AuraVax's CEO. "Our expectation is that NanoSTING-001 will reduce the seasonal disease burden of respiratory infections and provide a novel countermeasure to help mute the onset of emerging respiratory pathogens."
Platform Technology Pipeline
AuraVax's NanoSTING platform extends beyond NanoSTING-001 to include NanoSTING-002 (搜索), an intranasal mucosal adjuvant designed to augment immune responses to multiple vaccines. This broader pipeline approach positions the company to address various aspects of respiratory infection prevention and treatment through STING (搜索) pathway modulation.